Contents
Clinical trial facilities provide people with opportunities to take part in research studies. New Jersey is home to a number of reputable facilities, like the Princeton Medical Institute and Rowan University School of Osteopathic Medicine.
Education and research go hand in hand. By participating in clinical trials, volunteers help shape the healthcare landscape of tomorrow.
Clinical Trials For Disease Areas in New Jersey
Clinical research trials in New Jersey are constantly looking for new medications and treatments to treat diseases. More than 60 diseases are studied in NJ every day. Some of the key disease areas are cancer research, mental health, autoimmune disorders, and genetic and rare disorders.
For example, in 2023, a clinical trial provided an 8-year-old girl from New Jersey with hope for managing a rare disease. Mya Trujillo-Roman was diagnosed with idiopathic nephrotic syndrome. To reduce the risk of side effects, she was enrolled in a clinical trial that uses a novel biologic treatment. The plan is to treat the young girl with this new biologic.
Here is a list of other ongoing and future clinical trials that could prove useful.
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Recruiting
The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or multiple myeloma, and have a family member with one of these disorders or 2) they are a member of a family with a lymphoproliferative disorder, including Hodgkin's disease a... Read More
The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or multiple myeloma, and have a family member with one of these disorders or 2) they are a member of a family with a lymphoproliferative disorder, including Hodgkin's disease and/or, non-Hodgkin's lymphoma or a second cancer after Hodgkin's disease. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
01/21/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +1 locations
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth, Middletown, New Jersey
Conditions: Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, Renal Cancer
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
Recruiting
This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.
This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread. Read Less
Gender:
MALE
Ages:
All
Trial Updated:
03/20/2025
Locations: Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey +2 locations
Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey
Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey
Conditions: Prostate Cancer
Discarded Materials Study
Recruiting
Use of discarded embryos to advance laboratory expertise and technology in the area of human embryo development and assisted reproductive technologies
Use of discarded embryos to advance laboratory expertise and technology in the area of human embryo development and assisted reproductive technologies Read Less
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/04/2025
Locations: Reproductive Medicine Associates of new Jersey, Basking Ridge, New Jersey
Reproductive Medicine Associates of new Jersey, Basking Ridge, New Jersey
Conditions: Infertility
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Recruiting
The purpose of this 1 year study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in New York City hospitals, like meeting with a Social Worker or a Patient Navigator (a person who provides personal hospital guidance).
The purpose of this 1 year study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in New York City hospitals, like meeting with a Social Worker or a Patient Navigator (a person who provides personal hospital guidance). Read Less
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
02/19/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
Conditions: Cancer Patients
Verapamil for Neuroprotection in Stroke
Recruiting
The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.
The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care. Read Less
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/15/2025
Locations: AtlantiCare Regional Medical Center, Atlantic City, New Jersey
AtlantiCare Regional Medical Center, Atlantic City, New Jersey
Conditions: Ischemic Stroke
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents.
Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents.
Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (aged 6-17 years) with a history of migraine will be enrolled. The study will include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort). Participants aged 6-11 years in the PK Cohort will receive Dose A or Dose B of Ubrogepant for PK analysis to determine dose selection for the main study. In the main study, after dose selection, children aged 6-11 years will be randomized to receive either low or high dose of Ubrogepant or placebo. There is a 1 in 3 chance that a participant will be assigned to placebo. Adolescents aged 12-17 years will be randomized to receive either low or high dose of Ubrogepant or placebo with a 1 in 3 chance of placebo assignment.
For qualifying migraine attacks, participants will receive oral tablets of the double-blind study intervention. There will be an option to take a second dose of double-blind study intervention (identical to initial dose), or rescue medication, at least 2 hours after the initial dose, for headache of moderate/severe intensity. Around 1059 participants will be enrolled in the study in approximately 120 sites in the United States. The study duration will be up to 6 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. Read Less
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/11/2025
Locations: Hunterdon Neurology /ID# 245648, Annandale, New Jersey +2 locations
Hunterdon Neurology /ID# 245648, Annandale, New Jersey
Goryeb Children's Hospital /ID# 229507, Morristown, New Jersey
CVS HealthHUB - Runnemede /ID# 234233, Runnemede, New Jersey
Conditions: Migraine
A Study of Belantamab Mafodotin and Nirogacestat in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Recruiting
The purpose of this study is to find out whether combination treatment with the study drugs belantamab mafodotin and nirogacestat is a safe treatment for people who have relapsed or refractory multiple myeloma. The researchers will test different doses of belantamab mafodotin to find the safest dose to give with nirogacestat. They also want to find out whether belantamab mafodotin plus nirogacestat is an effective treatment for this type of bone marrow cancer, and will do tests that show whether... Read More
The purpose of this study is to find out whether combination treatment with the study drugs belantamab mafodotin and nirogacestat is a safe treatment for people who have relapsed or refractory multiple myeloma. The researchers will test different doses of belantamab mafodotin to find the safest dose to give with nirogacestat. They also want to find out whether belantamab mafodotin plus nirogacestat is an effective treatment for this type of bone marrow cancer, and will do tests that show whether the study treatment slows or stops the growth of cancer. Read Less
Gender:
All
Ages:
18 years and above
Trial Updated:
03/02/2022
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
Conditions: Multiple Myeloma
CONVERGE Post-Approval Study (PAS)
Recruiting
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD. Read Less
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/02/2025
Locations: AtlantiCare Medical Center, Atlantic City, New Jersey
AtlantiCare Medical Center, Atlantic City, New Jersey
Conditions: Chronic Atrial Fibrillation
Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin
Recruiting
The goal of this study is to visualize the deposition of topical 0.3% roflumilast (Zoryve) compared to vehicle using Line-Field Optical Coherence Tomography (LC-OCT) in vivo in healthy skin. We hypothesize that the application of topical 0.3% roflumilast (Zoryve) will result in distinct patterns of deposition within the epidermal and dermal layers compared to the vehicle. Specifically, we anticipate observing deeper penetration and more uniform distribution of roflumilast within the skin layers,... Read More
The goal of this study is to visualize the deposition of topical 0.3% roflumilast (Zoryve) compared to vehicle using Line-Field Optical Coherence Tomography (LC-OCT) in vivo in healthy skin. We hypothesize that the application of topical 0.3% roflumilast (Zoryve) will result in distinct patterns of deposition within the epidermal and dermal layers compared to the vehicle. Specifically, we anticipate observing deeper penetration and more uniform distribution of roflumilast within the skin layers, indicative of enhanced efficacy, as visualized by LC-OCT imaging. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Rao Dermatology, Atlantic Highlands, New Jersey
Rao Dermatology, Atlantic Highlands, New Jersey
Conditions: Healthy Skin
Effect of 60-day Peripheral Nerve Stimulation (PNS) in Alleviating Pain and Improving Function After Acute Thoracolumbar Compression Fracture
Recruiting
The purpose of this study is to track and investigate the outcomes of female patients with acute thoracolumbar compression fractures, focusing on pain management and functional improvement. The study will investigate patients whose compression fractures are within 3 months or less and measure pain scores, using the Numeric Rating Scale (NRS) and Brief Pain Inventory (BPI) and quality of life using the PROMIS questionnaire at 1-week prior to intervention and then 2 weeks, 3 months and 6 months po... Read More
The purpose of this study is to track and investigate the outcomes of female patients with acute thoracolumbar compression fractures, focusing on pain management and functional improvement. The study will investigate patients whose compression fractures are within 3 months or less and measure pain scores, using the Numeric Rating Scale (NRS) and Brief Pain Inventory (BPI) and quality of life using the PROMIS questionnaire at 1-week prior to intervention and then 2 weeks, 3 months and 6 months post PNS implantation.
The primary aim is to assess pain reduction among participants that receive the 60-day PNS intervention. The secondary aim is to analyze functional outcomes and quality of life documented in PROMs (Patient Reported Outcomes Measures) provided by CareSense a digital data collection system. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University Orthopaedic Associates, Avenel, New Jersey +2 locations
University Orthopaedic Associates, Avenel, New Jersey
University Orthopaedic Associates, Morganville, New Jersey
University Orthopaedic Associates, Somerset, New Jersey
Conditions: Thoracolumbar Compression Fractures
Paid Clinical Trials in New Jersey
Participating in medical research creates a dynamic partnership for both participants and healthcare experts. By joining paid clinical trials in New Jersey, participants get access to cutting-edge therapies and get compensated for their efforts.
The financial reward is one of the most compelling aspects of joining these trials. NJ paid clinical trials provide tangible benefits, even in the form of other reimbursements. Such as covering for travel fees, gas, or accommodations.
Clinical Trials For Health Volunteers in New Jersey
Health volunteers can help medical experts move science forward. They are a valuable component of any discovery or innovation made in the field of medicine.
If you want to take an active role in your own healthcare, contribute to medical research in New Jersey, and gain access to new research treatments before they become available for commercial use, check out the trial list below.
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
Recruiting
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily by an automated coagulometer device.
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily by an automated coagulometer device. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/09/2024
Locations: Frontage Clinical Services, Secaucus, New Jersey
Frontage Clinical Services, Secaucus, New Jersey
Conditions: Healthy
A Study Investigating Lu AG22515 in Healthy Adults
Recruiting
The main goal of this study is to learn more about the safety of a drug called Lu AG22515. During the trial, healthy adult participants will receive a single dose of Lu AG22515 or a placebo (normal saline solution).
The main goal of this study is to learn more about the safety of a drug called Lu AG22515. During the trial, healthy adult participants will receive a single dose of Lu AG22515 or a placebo (normal saline solution). Read Less
Gender:
All
Ages:
Between 19 years and 60 years
Trial Updated:
03/21/2022
Locations: Frontage Clinical Services, Inc., Secaucus, New Jersey
Frontage Clinical Services, Inc., Secaucus, New Jersey
Conditions: Healthy Participants
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer
Recruiting
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC.
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: United Theranostics, Princeton, New Jersey
United Theranostics, Princeton, New Jersey
Conditions: Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
Brain Criticality, Oculomotor Control, and Cognitive Effort
Recruiting
The project examines electroencephalography, MRI, and behavioral measures indexing flexibility (critical state dynamics) in the brain when healthy young adults do demanding cognitive tasks, and in response to transcranial magnetic stimulation.
The project examines electroencephalography, MRI, and behavioral measures indexing flexibility (critical state dynamics) in the brain when healthy young adults do demanding cognitive tasks, and in response to transcranial magnetic stimulation. Read Less
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/05/2024
Locations: Center for Advanced Human Brain Imaging Research, Piscataway, New Jersey
Center for Advanced Human Brain Imaging Research, Piscataway, New Jersey
Conditions: Healthy
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD).
Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it.
This is a 2-part study and will last approximately 29 weeks for Par... Read More
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD).
Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it.
This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part. Read Less
Gender:
ALL
Ages:
Between 45 years and 85 years
Trial Updated:
06/24/2025
Locations: CenExel-HRI, Marlton, New Jersey
CenExel-HRI, Marlton, New Jersey
Conditions: Alzheimer Disease, Healthy
Ultralow Dose PET Imaging for PSMA Expression
Recruiting
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard?
Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard?
Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours Read Less
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/01/2025
Locations: Nuclear Imaging Institute, Englewood, New Jersey
Nuclear Imaging Institute, Englewood, New Jersey
Conditions: Healthy Volunteer, Prostate CA
Ultralow Dose PET Imaging of 18F-FDG Uptake
Recruiting
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDG and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours.
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDG and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours. Read Less
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/01/2025
Locations: Nuclear Imaging Institute, Englewood, New Jersey
Nuclear Imaging Institute, Englewood, New Jersey
Conditions: Healthy Volunteer, Cancer
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
Recruiting
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-Florbetapir or 18F-Flutemetamo... Read More
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours Read Less
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/01/2025
Locations: Nuclear Imaging Institute, Englewood, New Jersey
Nuclear Imaging Institute, Englewood, New Jersey
Conditions: Healthy Volunteer, Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia
A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)
Recruiting
Researchers are looking for new medicines to prevent Human Immunodeficiency Virus Type 1 (HIV-1) infection. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Medicines to prevent HIV-1 infection are called pre-exposure prophylaxis (PrEP). Some people may have trouble following a PrEP plan because it involves either taking medicine everyday by mouth or getting injections (shots) often.
MK-8527 is a study medicine designed to prevent HIV-1 infection.... Read More
Researchers are looking for new medicines to prevent Human Immunodeficiency Virus Type 1 (HIV-1) infection. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Medicines to prevent HIV-1 infection are called pre-exposure prophylaxis (PrEP). Some people may have trouble following a PrEP plan because it involves either taking medicine everyday by mouth or getting injections (shots) often.
MK-8527 is a study medicine designed to prevent HIV-1 infection. MK-8527 is different from standard (usual) PrEP because it is taken once a month, by mouth, as a tablet.
The goal of this study is to learn if taking a higher-than-normal dose of MK-8527 increases the QT interval (a measure of heart rhythm) by a certain amount. Read Less
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/20/2025
Locations: Hassman Research Institute Marlton Site (0001), Marlton, New Jersey
Hassman Research Institute Marlton Site (0001), Marlton, New Jersey
Conditions: Healthy
Neurofeedback to Reduce Spontaneous Recovery of Threat Expectancy
Recruiting
This study tests the efficacy of a new behavioral intervention with the goal of reducing spontaneous recovery of threat expectancy in healthy adults. This real-time functional magnetic resonance imaging (fMRI) neurofeedback intervention delivers feedback based on a functional connection between the prefrontal cortex and the hippocampus.
This study tests the efficacy of a new behavioral intervention with the goal of reducing spontaneous recovery of threat expectancy in healthy adults. This real-time functional magnetic resonance imaging (fMRI) neurofeedback intervention delivers feedback based on a functional connection between the prefrontal cortex and the hippocampus. Read Less
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
08/11/2025
Locations: Princeton Neuroscience Institute, Princeton, New Jersey
Princeton Neuroscience Institute, Princeton, New Jersey
Conditions: Healthy
Medical Discoveries and Innovation in New Jersey
New Jersey is the nerve center of many discoveries and innovations that have left a mark on the healthcare industry. Here is a list of the scientific achievements, whose impact could be felt even today.
- Discovery of Streptomycin: Selman Waksman discovered the antibiotic streptomycin and was awarded a Nobel Prize for it. He spent most of his career at Rutgers University, New Jersey.
- Biotech research: New Jersey is the state of innovation when it comes to biotechnology. Exactly 13 out of 20 pharmaceutical companies in the globe are found here. This is why NJ takes the #2 spot in the United States for biotech strength.
- Neurological disorder insights: Rutger’s scientists found brain cell insights that can help provide novel treatment solutions for neurological-based conditions. They found that oligodendrocyte cells in the brain are fundamentally different from those in the spinal cord in terms of their metabolic processes.
Why New Jersey Is A Great Place For Clinical Research
For clinical research in New Jersey to advance, more patient data is necessary. The population here is diverse. It comprises of 53.5% White, 21.5% Hispanic, 13% Black, 10.1% Asian, and 1.6% multiracial.